Adalimumab (Tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina

Molecular Vision

Volumn 19, Issue , 2013, Pages 894-903

  Fernandez Bueno, Ivan ^a,b,c   Garcia Gutierrez, M T ^a,b   Srivastava, G K ^a,b,c   Gayoso, M J ^d   Gonzalo Orden, J M ^e   Pastor, J C ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c Regenerative Medicine and Cell Therapy Networking Center of 'Castilla y León'   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

^e UNIVERSITY OF LEÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BINDING PROTEIN; CELLULAR RETINALDEHYDE BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; ISOLECTIN B4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; EYEBALL; FROZEN SECTION; GLIOSIS; IMMUNOREACTIVITY; MACROPHAGE; MICROGLIA; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEUROEPITHELIAL LAYER; SUPERNATANT; SWINE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARRIER PROTEINS; CELL CULTURE TECHNIQUES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; PLANT LECTINS; RETINA; STAINING AND LABELING; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876572993     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. de la Rúa ER, Pastor JC, Fernandez I, Sanabria MR, Garcia-Arumi J, Martinez-Castillo V, Coco R, Manzanas L, Miranda I. Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1. Br J Ophthalmol 2008; 92:523-5. [PMID: 18211938].
2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 1998; 43:3-18. [PMID: 9716190].
3. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995; 79:953-60. [PMID: 7488586].
4. Baudouin C, Hofman P, Brignole F, Bayle J, Loubiere R, Gastaud P. Immunocytology of cellular components in vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Ophthalmologica 1991; 203:38-46. [PMID: 1766640].
5. Fisher SK, Lewis GP. Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res 2003; 43:887-97. [PMID: 12668058].
6. Pastor JC, Mendez MC, de la Fuente MA, Coco RM, Garcia-Arumi J, Rodriguez de la Rua E, Fernandez N, Saornil MA, Gayoso MJ. Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. Ophthalmic Res 2006; 38:193-200. [PMID: 16679807].
7. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25:397-424. [PMID: 16839797].
8. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res 2002; 21:127-44. [PMID: 11906814].
9. Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, Grierson I. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology 1993; 100:43-6. [PMID: 8094546].
10. Yang P, de Vos AF, Kijlstra A. Macrophages in the retina of normal Lewis rats and their dynamics after injection of lipopolysaccharide. Invest Ophthalmol Vis Sci 1996; 37:77-85. [PMID: 8550337].
11. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998; 212:410-4. [PMID: 9787233].
12. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol 1999; 83:1296-9. [PMID: 10535861].
13. Limb GA, Daniels JT, Pleass R, Charteris DG, Luthert PJ, Khaw PT. Differential expression of matrix metalloproteinases 2 and 9 by glial Muller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha. Am J Pathol 2002; 160:1847-55. [PMID: 12000736].
14. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002; 22:RC216-[PMID: 11917000].
15. Caicedo A, Espinosa-Heidmann DG, Pina Y, Hernandez EP, Cousins SW. Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp Eye Res 2005; 81:38-47. [PMID: 15978253].
16. Lewis GP, Sethi CS, Carter KM, Charteris DG, Fisher SK. Microglial cell activation following retinal detachment: a comparison between species. Mol Vis 2005; 11:491-500. [PMID: 16052164].
17. Mertsch K, Hanisch UK, Kettenmann H, Schnitzer J. Characterization of microglial cells and their response to stimulation in an organotypic retinal culture system. J Comp Neurol 2001; 431:217-27. [PMID: 11170001].
18. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138:648-50. [PMID: 15488796].
19. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, Michaud N, Hafezi-Moghadam A, Miller JW, Benowitz LI. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26:12633-41. [PMID: 17151265].
20. de Kozak Y, Cotinet A, Goureau O, Hicks D, Thillaye-Goldenberg B. Tumor necrosis factor and nitric oxide production by resident retinal glial cells from rats presenting hereditary retinal degeneration. Ocul Immunol Inflamm 1997; 5:85-94. [PMID: 9234372].
21. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010; 30:1601-8. [PMID: 21060271].
22. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30:1530-5. [PMID: 20924267].
23. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117:1612-6. [PMID: 20378179].
24. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008; 19:535-40. [PMID: 18854699].
25. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011; 31:298-303. [PMID: 21099452].
26. Caffé AR, Visser H, Jansen HG, Sanyal S. Histotypic differentiation of neonatal mouse retina in organ culture. Curr Eye Res 1989; 8:1083-92. [PMID: 2612197].
27. Katsuki H, Yamamoto R, Nakata D, Kume T, Akaike A. Neuronal nitric oxide synthase is crucial for ganglion cell death in rat retinal explant cultures. J Pharmacol Sci 2004; 94:77-80. [PMID: 14745122].
28. Cossenza M, Cadilhe DV, Coutinho RN, Paes-de-Carvalho R. Inhibition of protein synthesis by activation of NMDA receptors in cultured retinal cells: a new mechanism for the regulation of nitric oxide production. J Neurochem 2006; 97:1481-93. [PMID: 16606372].
29. Saikia P, Maisch T, Kobuch K, Jackson TL, Baumler W, Szeimies RM, Gabel VP, Hillenkamp J. Safety testing of indocyanine green in an ex vivo porcine retina model. Invest Ophthalmol Vis Sci 2006; 47:4998-5003. [PMID: 17065519].
30. Tura A, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 2009; 50:452-61. [PMID: 18757509].
31. Caffé AR, Ahuja P, Holmqvist B, Azadi S, Forsell J, Holmqvist I, Soderpalm AK, van Veen T. Mouse retina explants after long-term culture in serum free medium. J Chem Neuroanat 2001; 22:263-73. [PMID: 11719023].
32. Ogilvie JM, Speck JD, Lett JM, Fleming TT. A reliable method for organ culture of neonatal mouse retina with long-term survival. J Neurosci Methods 1999; 87:57-65. [PMID: 10065994].
33. Caffé AR, Soderpalm A, van Veen T. Photoreceptor-specific protein expression of mouse retina in organ culture and retardation of rd degeneration in vitro by a combination of basic fibroblast and nerve growth factors. Curr Eye Res 1993; 12:719-26. [PMID: 8222732].
34. Kuhrt H, Walski M, Reichenbach A, Albrecht J. Rabbit retinal organ culture as an in-vitro model of hepatic retinopathy. Graefes Arch Clin Exp Ophthalmol 2004; 242:512-22. [PMID: 14986013].
35. Fernandez-Bueno I, Pastor JC, Gayoso MJ, Alcalde I, Garcia MT. Muller and macrophage-like cell interactions in an organotypic culture of porcine neuroretina. Mol Vis 2008; 14:2148-56. [PMID: 19052655].
36. Fisher SK, Lewis GP, Linberg KA, Verardo MR. Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog Retin Eye Res 2005; 24:395-431. [PMID: 15708835].
37. Azadi S, Johnson LE, Paquet-Durand F, Perez MT, Zhang Y, Ekstrom PA, van Veen T. CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res 2007; 1129:116-29. [PMID: 17156753].
38. Liljekvist-Larsson I, Johansson K. Studies of host-graft interactions in vitro. J Neural Eng 2007; 4:255-63. [PMID: 17873428].
39. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91:319-24. [PMID: 17035274].
40. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007; 21:824-5. [PMID: 16601736].
41. Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, Adachi M. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004; 126:1473-9. [PMID: 15539715].
42. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997; 14:145-53. [PMID: 9039978].
43. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114-[PMID: 16859506].
44. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194:486-92. [PMID: 16845632].
45. Cuenca N, De Juan J, Kolb H. Substance P-immunoreactive neurons in the human retina. J Comp Neurol 1995; 356:491-504. [PMID: 7560262].
46. Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, Charteris DG. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2005; 46:329-42. [PMID: 15623793].
47. Charteris DG, Downie J, Aylward GW, Sethi C, Luthert P. Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:93-100. [PMID: 16612635].
48. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994; 13:791-8. [PMID: 7851114].
49. Pastor JC, Fernandez-Bueno I, Garcia M, Gayoso M, Corell A, Reinoso R, Enriquez de Salamanca A, Garcia C. Neuroretinal reactive gliosis changes were not appreciable in the presence of macrophage-like cells that do not produce significant TNFα and/or IL-1b levels. Preliminary results. ARVO Annual Meeting; 2010 May 2-6; Fort Lauderdale (FL).
50. Jackson TL, Hillenkamp J, Williamson TH, Clarke KW, Almubarak AI, Marshall J. An experimental model of rhegmatogenous retinal detachment: surgical results and glial cell response. Invest Ophthalmol Vis Sci 2003; 44:4026-34. [PMID: 12939325].
51. Iandiev I, Uckermann O, Pannicke T, Wurm A, Tenckhoff S, Pietsch UC, Reichenbach A, Wiedemann P, Bringman A, Uhlmann S. Glial cell reactivity in a porcine model of retinal detachment. Invest Ophthalmol Vis Sci 2006; 47:2161-71. [PMID: 16639028].
52. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P, Chevez-Barrios P, Takahashi W. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008; 246:907-11. [PMID: 18414888].
53. Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 2009; 247:1119-25. [PMID: 19296122].
54. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323-32. [PMID: 17636564].
55. Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci 2009; 50:4429-35. [PMID: 19369237].